- Emcure Pharmaceuticals reported 33.7% net profit growth to Rs 326 crore in Q2
- Revenue rose 24.2% year-on-year to Rs 2,820 crore for the September quarter
- Ebitda increased 23.5% to Rs 587.3 crore with a stable margin of 20.8%
Emcure Pharmaceuticals Ltd reported strong quarterly earnings for the September quarter, with net profit, revenue, and Ebitda registering double-digit growth compared with the corresponding period last year.
Net profit rose 33.7% year-on-year to Rs 326 crore, while revenue increased 24.2% to Rs 2,820 crore. Ebitda also grew 23.5% to Rs 587.3 crore, according to an exchange filing by the company on Tuesday.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
The Ebitda margin, however, remained largely stable at 20.8%, compared with 20.9% in the year-ago quarter.
Key Results Highlights
- Net Profit: Increased 33.7% year-on-year to Rs 326 crore from Rs 244 crore.
- Revenue: Rose 24.2% to Rs 2,820 crore from Rs 2,270 crore.
- Ebitda: Grew 23.5% to Rs 587.3 crore from Rs 475.4 crore.
- Ebitda Margin: Stood at 20.8%, compared with 20.9% in the year-ago quarter.
READ | Graphite India Q2 Results: Net Profit Grows Nearly 25% Despite One-Time Loss, Margin Expands Sharply
International Business Leads Growth
Emcure's international business continued to drive growth, with revenue from overseas markets increasing 34.5% year-on-year during the quarter. Domestic revenue grew 12%, marking the second consecutive quarter of double-digit growth.
Within international markets, revenue from the rest of the world region increased 41.1%, while Europe and Canada reported growth of 36% and 24%, respectively. The company attributed domestic growth to strong performance in women's health, cardio-metabolic, and central nervous system therapies. Key brands, including Orofer XT, Orofer FCM, and Rosuvas EZ, reported growth of 39%, 39%, and 64%, respectively, according to IQVIA data.
Growth Across International Markets
In Europe, growth was supported by the existing business and new product launches, while Canada benefited from market share gains and recent launches. In the rest of the world markets, new product launches across Latin America, the CIS, Asia, and Africa supported growth. Emcure also highlighted that it received 20 approvals in these markets during the quarter.
Stock Price Performance
The stock has jumped over 9% in intraday trade after the announcement of the Q2 earnings. At around 2:35 p.m., the stock is trading at Rs 2,059.6 apiece on the NSE, gaining from its previous close at Rs 1,883.5.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.